Three listings are currently scheduled for the week ahead, although other issuers may join the calendar throughout the week.
Phase 1 oncology biotech Boundless Bio (BOLD) plans to raise $100 million at a $396 million market cap. The company is focused on developing therapies for oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA). Its lead ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1, which manages ecDNA replication and transcription in cancer cells. BBI-355 is currently being studied in a first-in-human, Phase 1/2 trial in patients with oncogene amplified cancers, with preliminary data expected in the 2H24.
Singapore-based telehealth company Mobile-health Network Solutions (MNDR) plans to raise $10 million at a $153 million market cap. The company provides services through its MaNaDr platform, where users throughout the APAC region can access a range of telehealth solutions, comprising teleconsultation services and personalized services. The company also operates one brick-and-mortar GP clinic in Singapore.
Australia-based fitness program provider Alta Global Group (MMA) plans to raise $7 million at a $58 million market cap. Alta offers a platform for martial arts and combat sports, featuring four core products: the Warrior Training Program, UFC Fight Fit Program, Alta Academy, and the Alta Community. To date, the company has monetized its Warrior Training Program.
| U.S. IPO Calendar | |||
|---|---|---|---|
| Issuer Business | Deal Size Market Cap | Price Range Shares Filed | Top Bookrunners |
| Mobile-health Network (MNDR) | $10M $153M | $4 - $5 2,250,000 | Network 1 |
| Provides a platform for telehealth and other healthcare services in the APAC region. | |||
| Alta Global Group (MMA) Manly, Australia | $7M $58M | $4 - $6 1,300,000 | ThinkEquity |
| Provides martial art and combat sport training through a network of partner gyms. | |||
| Boundless Bio (BOLD) San Diego, CA | $100M $396M | $15 - $17 6,250,000 | Goldman Leerink Partners |
| Phase 1 biotech developing inhibitor therapies for oncogene amplified tumors. | |||
Sign up for a free trial of our premium platform, IPO Pro. To get our IPO calendar in your inbox, register here.
Street research is expected for one company in the week ahead, and three lock-up periods will be expiring. For access to Street research and lock-up expiration dates, sign up for a free trial of IPO Pro.
IPO Market Snapshot
The Renaissance IPO Indices are market cap weighted baskets of newly public companies. As of 3/21/2024, the Renaissance IPO Index was up 11.1% year-to-date, while the S&P 500 was up 10.3%. Renaissance Capital's IPO ETF (NYSE: IPO) tracks the index, and top ETF holdings include Kenvue (KVUE) and Coinbase Global (COIN). The Renaissance International IPO Index was down 0.5% year-to-date, while the ACWX was up 4.9%. Renaissance Capital’s International IPO ETF (NYSE: IPOS) tracks the index, and top ETF holdings include Wise and Porsche.
